Loading...
•
Sep 30, 2021
Leap Therapeutics Q3 2021 Earnings Report
Reported financial results for the third quarter ended September 30, 2021.
Key Takeaways
Leap Therapeutics reported a net loss of $11.1 million for the third quarter of 2021, with license revenues of $0.4 million. Research and development expenses increased to $10.1 million, and cash and cash equivalents totaled $124.8 million at the end of the quarter.
Presented positive new data at ESMO of DKN-01 in combination with BeiGene’s tislelizumab and chemotherapy.
Data demonstrated compelling overall response rates in patients with first-line gastric or gastroesophageal junction (G/GEJ) cancer.
Observed particularly strong responses in patients whose tumors expressed high levels of DKK1 or low PD-L1.
Looking forward to presenting additional data from the DisTinGuish study early next year and aggressively advancing DKN-01 into the next stages of development in G/GEJ and other cancers.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...